Foreign Investor Leads Class Action V. Drug Co.
A Luxemburg-based investment firm has been appointed lead plaintiff in a consolidated shareholder class action against anti-cancer drug maker GPC Biotech AG despite concerns over a foreign investor's rights in U.S....To view the full article, register now.
Already a subscriber? Click here to view full article